

Profiles
March 31, 2016

Robert C. Smith, M.D., Ph.D.

PUBLICATIONS

1. Smith, R.C.: Discussion tasks as a measure of influence structure and reversal of role structure in normal families: Implications for the study of pathological families. *J. Psychiat Res.* 8:51-61, 1970.
2. Smith, R.C.: Verbal discussion vs note passing tasks in the study of family role structure. *J. Nerv. Men. Dis.* 152:173-183, 1971.
3. Smith, R.C., Carlin, J.: Behavior modification using interlocking reinforcement on a short-term psychiatric ward. *Arch. Gen. Psychiat.* 27:386-390, 1972.
4. Smith, R.C., Davis, JM, Schlemmer, F.: Relative potencies of amphetamine and methylphenidate on mood and activation in man and stereotyped behavior and locomotor activity in rats. *Abst. Soc. for Neurosci.* 4th Annual Meeting, p. 642, 1974.
5. Smith, R.C.: Alcohol and acceptance of social influence: An experimental study. *Psychopharmacologia* 36:357-366, 1974.
6. Smith, R.C., Dekirmenjian, H., Davis, JM et al: Blood level, mood and MHPG response to diazepam in man. *Psychofarmacol. Bull.* 11:21-23, 1975.
7. Smith, R.C., Parker, E.S., Nobel, E.P.: The effect of alcohol on some formal aspects of verbal social communication. *Arch. Gen. Psychiat.* 32:1394-98, 1975.
8. Smith, R.C., Parker, E.S., Nobel, E.P.: Alcohol and affect in dyadic social interaction. *Psychosomatic Med.* 37:25-40, 1975.
9. Smith, R.C., Boggan, W.O., Freedman, D.X.: Effects of single vs multiple doses of LSD on rat brain tyrosine and catecholamines. *Psychopharmacologia* 42:271-276, 1975.
10. Smith, R.C., Davis, JM: Behavioral supersensitivity to apomorphine and amphetamine after chronic high dose haloperidol treatment. *Psychopharmacol. Comm.* 1:285-293, 1975.
11. Smith, R.C., et al: Blood level, mood, and MHPG responses to diazepam in man. In: *Pharmacokinetics, Psychoactive Drug Blood Levels and Clinical Response*, Gottschalk, L., and Merlis, S. (eds). Spectrum Books, New York, pp. 141-156, 1976.
12. Fishman, M.W., Smith, R.C., Schuster, C.R.: The effects of chlorpromazine on avoidance and escape responding in humans. *Pharmacol. Biochem. Behav.* 4:111-114, 1976.

13. Tamminga, C.T., Smith, R.C., Chang, S., Haraszti, J.S., Davis, JM: Depression with oral choline. *Lancet*, p. 905, 1976.
14. Seegraves, R.T., Smith, R.C.: Concurrent Psychotherapy and behavior therapy treatment of psychoneurotic outpatients. *Arch. Gen. Psychiat.* 33:756-763, 1976.
15. Smith, R.C., Davis, JM: Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine. *Life Sci.* 19:725-732, 1976.
16. Smith, R.C., Tamminga, C.T., Davis, JM: Effects of apomorphine on schizophrenic symptoms. *J. Neur. Transmission.* 40:171-176, 1977.
17. Smith, R.C., Tamminga, C.T., Haraszti, J., Garver, D., Froman, L., Davis, JM: Effects of dopamine agonists in tardive dyskinesia. *Am. J. Psychiat.* 134:763-768, 1977.
18. Tamminga, C.T., Smith, R.C., Chang, S., Erickson, S., Davis, JM: Cholinergic influences in tardive dyskinesia. *Am. J. Psychiat.* 134:769-774, 1977.
19. Crayton, J.W., Smith, R.C., Klass, D., Chang, S.: Electrophysiological (H-reflex) studies in patients with tardive dyskinesia: Comparison to other schizophrenic patients. *Am. J. Psychiat.* 134:775-781, 1977.
20. Smith, R.C., Davis, JM: Comparative effects of d-amphetamine, l- amphetamine, and methylphenidate on mood in man. *Psychopharmacol.* 53:1-12, 1977.
21. Smith, R.C., Meltzer, H.Y. Arora, R.C., Davis, JM: Effects of phencyclidine on 3H-catecholamine and 3H-serotonin uptake in synaptosomal preparations from rat brain. *Biochem. Pharmacol.* 26:1435-1439, 1977.
22. Smith, R.C., Dekirmenjian, H., Davis, JM, Crayton, J., Evans, H.: Plasma butaperazine in long-term chronic non-responding schizophrenics. *Comm. Psychopharmacol.* 1:319-324, 1977.
23. Tamminga, C.T., Smith, R.C., Pandey, G., Froman, L.A., Davis, JM: A neuroendocrine study of supersensitivity in Tardive Dyskinesia. *Arch Gen. Psychiat.* 34:1199-1203, 1977.
24. Davis, JM Janowsky, D., Tamminga, C.T., Smith, R.C.: Cholinergic mechanisms in schizophrenia, mania and depression. In: *Cholinergic Mechanisms and Psychopharmacology*, D. Jendon (ed.), Plenum, New York, 1977.
25. Bell, R.C.H., Smith, R.C.: Tardive Dyskinesia: Characterization and prevalence in a statewide system. *J. Clin. Psychiat.* 39:39-42, 46-47, 1978.
26. Smith, R.C., Narasimhachari, N., Davis, JM: Increased effect of apomorphine on homovanillic acid in rats terminated from chronic haloperidol. *J. Neural Transmission.* 42:159-162, 1978.
27. Smith, R.C., Leelavathi, D.E., Lauritzen, A.M.: Behavioral effects of dopamine agonists increase with age. *Comm. Psychopharmacol.* 2:39-43, 1978.
28. Tamminga, C.T., Shaffer, M., Smith, R.C., Davis, JM: Schizophrenic symptoms improve with apomorphine. *Science* 200:567-568, 1978.
29. Smith, R.C., Stritch, M.A., Klass, D.A.: Drug history and tardive dyskinesia. *Am. J. Psychiat.* 135:1402-1403, 1978.

30. Smith, R.C., Crayton, J.W., Tamminga, C., Dekirmenjian, H., Schoolar, R.C., Davis, JM: Blood levels of neuroleptic drugs, clinical response, and plasma prolactin in chronic non-responding schizophrenic patients, in *The Kinetics of Psychiatric Drugs*, Brunner/Mazel, New York, Schoolar, J.C., Claghorn, J.L. (eds). 137-170, 1979.
31. Smith, R.C., Dekirmenjian, H., Klass, D., Davis, JM: Blood levels of neuroleptic drugs in non-responding chronic schizophrenic patients. *Arch. Gen. Psychiat.* 36:579-584, 1979.
32. Smith, R.C, Strong, R., Hicks, P.B., Samorajski, T.: Behavioral evidence for supersensitivity after chronic bromocriptine administration. *Psychopharmacol.* 60:241-246, 1979.
33. Smith, R.C., Misra, C.H., Ho, B.T., Tansey, L.W.: Effects of age and chronic neuroleptics on measures of supersensitivity. In: *Catecholamine: Basic Clinical Frontiers*, Vol. 1, Usdin, E., Koplin, I.J., Barchas, J. (eds). Pergamon Press, New York, pp. 842-844, 1979.
34. Smith, R.C., Tamminga, CA., Crayton, J.W., Dekirmenjian, H., Davis, JM: Relationship of butaperazine blood levels to plasma prolactin in chronic schizophrenic patients. *Psychopharmacology* 66:29-33, 1979.
35. Fann, W.E., Smith, R.C., Davis, JM, Domino, E.: *Tardive Dyskinesia: Research and Treatment*, Spectrum Press, New York, 1980.
36. Seagraves, R.T., Smith, R.C.: Concurrent psychotherapy and behavior therapy: Treatment of Psychoneurotic outpatients. In: *The Interface Between Psychodynamic and Behavioral Therapies*, Marmor, J., Woods, S.M. (eds) Plenum Press, pp. 257-274, 1980.
37. Smith, R.C., Leelavathi, D.E.: Behavioral and biochemical studies of the effects of chronic neuroleptic drugs: Interaction with age. In: *Tardive Dyskinesia: Research and Treatment*, Smith, R.C., Fann, W.E., Davis, JM., Domino, E.F. (eds). Spectrum Press, New York, pp. 65-88, 1980.
38. Smith, R.C., Klass, N.D., Tritici, M.: History of neuroleptic drugs and tardive dyskinesia. In: *Tardive Dyskinesia: Research and Treatment*, Smith, R.C., Fann, W.E., Davis, JM, Domino, E.F. (eds). Spectrum Press, New York, pp. 309-314, 1980.
39. Smith, R.C., Tamminga, C., Davis, J.: Behavioral effects of apomorphine and amphetamine in tardive dyskinesia patients. In: *Tardive Dyskinesia: Research and Treatment*, Smith, R.C., Fann, W.E., Davis, JM, Domino, E.F. (eds). Spectrum Press, New York, pp. 333-345, 1980.
40. Tamminga, C., Smith, R.C., Pandey, G., Frohman, L., Davis, JM: Neuroendocrine effects of dopamine agonists in patients with tardive dyskinesia. In: *Tardive Dyskinesia: Research and Treatment*, Smith, R.C., Fann, W.E., Davis, JM, Domino, E.F. (eds). Spectrum Press, New York, pp. 345-354, 1980.
41. Tamminga, C., Smith, R.C., Davis, JM: Effects of cholinergic drugs on the involuntary movements of tardive dyskinesia. In: *Tardive Dyskinesia: Research and Treatment*, Smith, R.C., Fann, W.E., Davis, JM, Domino, E.F. (eds). Spectrum, New York, pp. 411-418, 1980.
42. Chan, C.H., Davis, JM, Smith, R.C., Reed, K.: Maintenance antipsychotic therapy and the risks of tardive dyskinesia. In: *Tardive Dyskinesia: Research and Treatment*, Fann, W.E., Smith, R.C., Davis, JM, Domino, E.F. (eds). Spectrum, New York, pp. 511-522, 1980.

43. Crane, G., Smith, R.C.: The prevalence of tardive dyskinesia. In: *Tardive Dyskinesia: Research and Treatment*, W.E., Smith, R.C., Davis, JM, Domino, E.F. (eds). Spectrum, New York, pp. 269-279, 1980.
44. Leelavathi, D.E., Smith, R.C.: Chronic neuroleptics and brain monoamine oxidase activity. *Biol. Psychiat.* 15:479-484, 1980.
45. Misra, C.H., Shelat, H.S., Smith, R.C.: Effect of age on adrenergic and dopaminergic receptor binding in rat brain. *Life Sci.* 27:521-526, 1980
46. Reed, K., Smith, RC., Schoolar, J.C., Hu, R., Leelavathi, DE., Mann, E., Lippman, L.: Cardiovascular effects of nortriptyline in geriatric patients. *Am. J. Psychiat.* 137:8, pp. 986-989, 1980.
47. Hsu, L.L., Smith, R.C., Rolsten, C., Leelavathi, D.E.: Effects of acute and chronic phencyclidine on neurotransmitter enzymes in rat brain. *Biochem. Pharmacol.* 29:2524-2526, 1980.
48. Smith, R.C., Taylor, D., Ho, B.T., Leelavathi, D.E.: Effects of acute and chronic administration of phencyclidine on tyrosine hydroxylase activity in rat striatum. *J. Neural Transmission.* 48:289-295, 1980.
49. Smith, R.C., Chojnacki, M., Hu, R., Mann, E.: Cardiovascular effects of therapeutic doses of tricyclic antidepressants: Importance of blood level monitoring. *J. Clin. Psychiat.* 41:57-63, 1980..
50. Smith, R.C., Strong, J.R., Strong, J: Aging and the behavioral effects of dopamine agonists in rodents. In: *Psychopharmacology of Aging*, Fann, WE. (ed), Spectrum Books, New York, pp. 135-143, 1980.
51. Smith, R.C., Biggs, C., Vroulis, G., Brinkman, S.: Effects of chronic administration of phencyclidine on stereotyped and ataxic behaviors in the rat. *Life Sci.* 28:1163-1174, 1981.
52. Smith, R.C., Misra, C.H., Leelavathi, D.E., Shelat, H., Allen, R., Schoolar, J., Gordon, J.: Receptor studies of the effects and blood levels of neuroleptic and antidepressant drugs. In: *Neuroreceptors: Basic and Clinical Aspects*, Chapter 14, Usdin, E., Bunney, W.E., Davis, JM (eds). John Wiley & Sons, New York and England, pp. 215-229, 1981.
53. Smith, R.C., Reed, K., Leelavathi, D.E., et al.: Pharmacokinetics and the effects of nortriptyline in geriatric patients. *Psychopharmacol. Bull.* 16:54-57, 1980.
54. Vroulis, G.A., Smith, R.C., Brinkman, S., Schoolar, J., Gordon, J.: The effects of lecithin on memory in patients with senile dementia of the Alzheimer's-type. *Psychopharmacol. Bull.* 17:127-128, 1981.
55. Chojnacki, M., Mann, E., Shvartsburd, A., Wingfield, C.W., Campbell, K., Smith, R.C.: Comparison of standard and halter-monitored-monitored EKGs in a patient treated with several antidepressants. *Res. Commun. in Chem. Path. and Pharmacol.* 6:103-111, 1980.
56. Chojnacki, M., Kralik, P., Allen, R., HO, B.T., Schoolar, J.C., Smith, R.C.: Treatment with neuroleptics decreases platelet MAO activity in schizophrenic patients. *Am. J. Psychiat.* 138:838-840, 1981.
57. Smith, R.C., Leelavathi, D.E., Hsu, L., Ho, B.T., Tansey, W., Taylor, D., Biggs, C.: Acute versus chronic administration of phencyclidine: Effects on behavior and brain biochemistry. In: *PCP Historical Current Perspectives*, Domino, E.F., (ed). NPP Books, Ann Arbor, Michigan, pp. 243- 291, 1981.

58. Misra, C.H., and Smith, R.C.: Effects of age on dopaminergic supersensitivity induced by chronic fluphenazine. *Commun. Psychopharmacol.* 4:411-415, 1981.
59. Leelavathi, D.E., Misra, C.H., Shelat, H., Smith, R.C.: Effects of acute and chronic administration of phencyclidine on dopaminergic receptors in rat striatum. *Commun. Psychopharmacol.* 4:417-424, 1981.
60. Smith, R.C., Vroulis, G., Misra, C.H., et al: Receptor techniques in the study of plasma levels of neuroleptics and antidepressant drugs. *Comm. Psychopharmacol.* 4:451-465, 1980.
61. Vroulis, G.A., Smith, R.C.: Cholinergic drugs and memory disorders in Alzheimer's-type Dementia. *Brain Neurotransmitter and Receptors in Aging and Age Related Disorders*, Raven Press, pp. 245-254, 1981.
62. Smith, R.C., Shelat, H.S., Sammeta, J., Misra, C.H.: Aging, receptors and neuroleptic drugs. *Brain Neurotransmitters and Receptors in Aging and Age-Related Disorders*, Raven Press, 231-243, 1981.
73. Brizzee, R.K., Samorajski, T., Smith, R.C., Brizzee, D.L.: The effect of age and chronic neuroleptic drug treatment on cell populations in the neostriatum of Fisher 344 rats. *Brain Neurotransmitter and Receptors in Aging and Age-Related Disorders*, Raven Press, 59-80, 1981.
64. Brinkman, S.D., Smith, R.C., Meyer, J.S., Vroulis, G., Shu, T., Gordon, J.R., Allen, R.H.: Lecithin and memory training in suspected Alzheimer's disease. *J. Gerontol.* 37 (1):4-9, 1982.
65. Smith, R.C., HO, B.T., Hsu, L., Vroulis, G.: Cholinesterase enzymes in the blood of patients with Alzheimer's disease. *Life Sci.* 30:543-546, 1982.
66. Smith, R.C., Vroulis, G., Shvartsburd, A., Allen, R., Lewis, N., Schoolar, J.C., Chojnacki, M., Johnson, R.: RBC and plasma levels of haloperidol and clinical response in schizophrenia. *Am. J. Psychiatry*, 139:1054-1056, 1982.
67. Vroulis, G., Smith, R.C., Schoolar, J.C., Dahlen, G., Katz, E., Misra, C.H.: Reduction of cholesterol risk factors by lecithin in patients with Alzheimer's disease. *Am. J. Psychiat.* 139:1633-1634, 1982.
68. Smith, R.C., Allen, R., Gordon, J., Misra, C., Schoolar, J.C., Wolff, J., Ho, B.T.: Biological and clinical studies of Tardive Dyskinesia. *Psychopharmacol. Bull.* 18:80-81, 1982.
69. Griffith, J.D., Smith, C.H., Smith, R.C.: Case Report: Paranoid psychosis in a patient receiving ibuprofen, a prostaglandin synthesis inhibitor. *J. Clin. Psychiat.* 43:499-500, 1982.
70. Smith, R.C., Ho, B.T., Kralik, P., Vroulis, G., Gordon, J., Wolff, J.: Platelet monoamine oxidase in Alzheimer's disease. *J. Gerontol.* 37:572-574, 1982.
71. Misra, C.H., Hicks, P., Rolsten, C., Smith, R.C., Schoolar, J.C.: Regional uptake of (35S)-cysteine in rat brain after arterial injection. *Res. Comm. Chem. Path. Pharmacol.* 37:155-158, 1982.
72. Ho, B.T., Smith, R.C., Kralik, P., Allen, R., Schoolar, J.C., Khan, M., DeJohn, C.: Effects of neuroleptics on platelet monoamine oxidase activity. *Biol. Psychiat.* 17:885-895, 1982.
73. Misra, C., Shelat, H., Smith, R.C.: Age effects dopamine receptor changes during chronic administration of fluphenazine. *Eur. J. Pharmacol.* 85:343-346, 1982.

74. Brizzee, K.R., Samorajski, T., Brizzee, D.L., Ordy, JM, Dunlap, W., Smith, R.C.: Age pigments and cell loss in the mammalian nervous system: Functional implications. *Brain Aging, Neuropath. Neuropharmacol.* 21:211- 229, 1983.
75. Shvartsburd, A., Dekirmenjian, H., Smith, R.C.: Blood levels of haloperidol in schizophrenic patients. *J. Clin. Psychopharmacol.* 3:7-12, 1983.
76. Smith, R.C., Reed, K., Wolff, J., Shvartsburd, A., Hu, J., Beller, S.: Case Report: Large variations in nortriptyline kinetics during long-term treatment of a geriatric patient. *Houston International Hospital, The Journal* pp. 21-28, 1982.
77. Smith, R.C., Allen, R., Gordon, J., Wolff, J.: A rating scale for tardive dyskinesia and parkinsonian symptoms. *Psychopharmacol. Bull.* 19:266-276, 1983.
78. Smith, R.C., Largen, J., Calderon, M., Schoolar, J.C., Shvartsburd, A., Ravichandran, G.K.: CAT scans and neuropsychological tests as predictors of clinical response in schizophrenics. *Psychopharmacol. Bull.* 19:505-509, 1983.
79. Smith, R.C., Misra, C.H., Allen, R., Gordon, J.: Dosage and blood levels of neuroleptics in tardive dyskinesia. *New Directions in Tardive Dyskinesia, Research, Modern Problems of Pharmacopsychiatry* 21:87-96, 1983.
80. Largen, J.W., Calderon, M., Smith, R.C.: Assymetries in the densities of white and gray matter in the brains of schizophrenic patients. *Am. J. Psychiatry*, 140:1060-1062, 1983
81. Shvartsburd, A., Nwokeafor, V., Smith, R.C.: Red blood cell and plasma levels of thioridazine and mesoridazine in schizophrenia patients. *Psychopharmacology* 82:55-61, 1984.
82. Ravichandran, G.K., Lu, R.B., Shvartsburd, A., Misra, C.H., Ho, B.T., Kahn, M., Smith, R.C.: Prolactin response to single and multiple doses of haloperidol in schizophrenic patients. *Psychiatry Res.* 11:61-69, 1984.
83. Smith, R.C., Calderon, M., Ravichandran, G.K., Largen, J., Shvartsburd, A., Gordon, J., Schoolar, J.C.: Nuclear Magnetic Resonance in Schizophrenia: A preliminary study. *Psychiatry Res.* 12:137-147, 1984.
84. Sajadi, C., Smith, R.C., Shvartsburd, A., Morton, V., Mirabi, M., Gordon, J.: Neuroleptic blood levels in outpatient maintenance therapy of schizophrenia. *Psychopharmacol. Bull.* 20:110-113, 1984.
85. Shvartsburd, A., Sajadi, C., Morton, V., Mirabi, M., Gordon, J., Smith, R.C.: Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients. *J. Clin. Psychopharmacol.* 4:194-198, 1984.
86. Sajadi, C., Smith, R.C., Shvartsburd, A., Morton, V., Gordon, J., Mirabi, M. Neuroleptic blood level monitoring in maintenance studies of schizophrenic outpatients. In: *The Chronically Mentally Ill: Research and Services*, M. Mirabi (ed), Spectrum Books, New York, pp. 143-158, 1984.
87. Smith, R.C., Vroulis, G., Johnson, R., Morgan, R: Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease. *Psychopharmacol. Bull.* 20:542-545, 1984.

88. Largen, J.W., Smith, R.C., Calderon, M., Baumgartner, R., Lu, R.B., Schoolar, J.C., Ravichandran, G.K. Abnormalities of brain structure and density in schizophrenia. *Biological Psychiatry*, 12, 991-1014, 1984.
89. Smith, R.C., Baumgartner, R., Ravichandran, G.K., Shvartsburd, A., Schoolar, J.C., Allen, P., Johnson, R: Plasma and red cell levels of thioridazine and clinical response in schizophrenia. *Psychiatry Res.* 12:287- 296, 1984.
90. Smith, R.C., Baumgartner, R., Misra, C.H., Mauldin, M., Shvartsburd, A., Ho, B.T., DeJohn, C.: Haloperidol: Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia; chemical vs radio- receptor plasma level assays. *Arch. Gen. Psychiatry.* 41:1044-1049, 1984.
91. Smith, R.C., Baumgartner, R., Burd, A., Ravichandran, G.K., Mauldin, M.: Haloperidol and thioridazine drug levels and clinical response in schizophrenia: Comparison of gas liquid chromatography and radioreceptor drug level assays. *Psychopharmacol. Bull.* 21:52-58, 1985.
92. Smith, R.C., Baumgartner, R., Calderon, M., Affas, A., Ravichandran, G.K. and Peters, I.D.: Magnetic Resonance Imaging Studies of Schizophrenia *Psychopharmacol. Bull.* 21: 588-594, 1985.
93. Smith, R.C., Baumgartner, R., Ravichandran, G.K., Mauldin, M., Burd, A., Vroulis, G., Gordon, J., Calderon, M.: Lateral ventricular enlargement and clinical response in schizophrenia. *Psychiatry Res.*, 14:241-253, 1985.
94. Smith, R.C., Baumgartner, R., Shvartsburd, A., Ravichandran, G.K., Vroulis, G., Mauldin, M.: Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia. *Psychopharmacology* 85:449-455, 1985.
95. Samorajski, T., Vroulis, G.A., and Smith, R.C.: Piracetam Plus Lecithin Trials in Senile Dementia of the Alzheimer Type. *Annals of the New York Academy of Sciences*, 478-481, 1985.
96. Smith, R. C., Baumgartner, R., Ravichandran, G.K., Largen, J., Calderon, M., Burd, A., Mauldin, M.: Cortical Atrophy and White Matter Density in the Brains of Schizophrenics and Clinical Response to Neuroleptics *Acta Psychiatrica Scandinavica* 75: 11-19, 1987.
97. Smith, R.C., Baumgartner, R., Calderon, M.: Magnetic Resonance Imaging Studies of the Brains of Schizophrenic Patients. *Psychiatry Res.* 20: 33- 46, 1987.
98. Kumar, V., Smith, R.C., Reed, K., Leelavathi, D.E.: Plasma levels and effects nortriptyline in geriatric depressed patients. *Acta Psychiatrica Scandinavica.* 75: 20-28,1987.
99. Smith, R.C.: Plasma Haloperidol Levels and Clinical Response. *Arch. Gen. Psychiatry* 44:1110 - 1112, 1987.
100. Smith, R.C., Kumar, V., Khera, G., Elble, R., Giacobini, E., Colliver, J.: Brain morphological measures and CSF acetylcholine in Alzheimer dementia. *Psychiatry Res.* 23:111-114, 1988.
101. Smith, R.C.: Is the dopaminergic supersensitivity of tardive dyskinesia valid. in Wolf, M., ed., *Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects.* American Psychiatric Press, Inc., Washington, D.C.,1988, pp. 3-21.

102. Kumar, V, Smith, R.C., Sherman, K.A., Ashford, W., Murphy, J. Giacobini, E., Colliver J.: Cortisol responses to cholinergic drugs in Alzheimer's disease. *Int. J. Clin. Pharmacology Therapy and Toxicology*, 26:471-476, 1988.
103. Smith, R.C., Largent J, Voulis G, Ravichandran G.K.: Neuropsychological test scores and clinical response to neuroleptic drugs in schizophrenic patients. *Comprehensive Psychiatry*, 33:139-145, 1992.
104. Smith, R.C.: Lower dose therapy with traditional neuroleptics in chronically hospitalized schizophrenic patients. *Arch Gen. Psychiatry*, 51:427-429, 1994.
105. Smith, RC, Kadewari, RP: Neurological soft signs and response to risperidone in chronic schizophrenia. *Biological Psychiatry*, 40:1056-1059, 1996.
106. Smith, RC, Chua, JW, Lipetsker, B, Bhattacharyya, A: Efficacy of risperidone in reducing positive and negative symptoms in medication refractory schizophrenia: An open prospective study. *J. Clinical Psychiatry*, 57:46-466, 1996.
107. Lindenmayer JP, Iskander A, Park M, Fotini-Sponia A, Czobor P, Smith R, Allen D: Clinical and neurocognitive effects of clozapine and risperidone in treatment refractory schizophrenics: A prospective study. *J. Clinical Psychiatry*, 59:521-527, 1998.
108. Smith RC, Hussain MI, Chowdhury SA, Stearns A: Stability of neurological soft signs in chronically hospitalized schizophrenic patients. *J. Neuropsychiatry Clin. Neurosciences*, 11: 91-96, 1999.
109. Smith RC, Kadewari RP, Rosenberger JR, Bhattacharyya A: Nonresponding schizophrenia; Differentiation by neurological signs and neuropsychological tests. *Schizophrenia Bulletin*, 25:813-826, 1999.
110. Smith RC, Infante M, Ali A, Nigam S: Effects of cigarette smoking on psychopathology scores in schizophrenic patients: An experimental study, *Substance Abuse* 22:175-185, 2001
111. Lindenmayer JP, Smith RC, Singh A, Parker B, Chou E, Kotsaftis, A: Hyperglycemia in schizophrenic patients treated with olanzapine, *J. Clinical Psychopharmacology*, 21: 351-353, 2001.
112. Smith RC, Infante M, Singh A, Khandat A: Olanzapine's effects on neurocognitive functioning in medication refractory schizophrenia. *Int. J. Neuropsychopharmacology*, 4:239-250, 2001.
113. Lindenmayer, JP, Nathan A-M, Smith RC: Hyperglycemia associated with the use of atypical antipsychotics. *J. Clin. Psychiatry*, 62: (Supp 13) 39-44, 2001.
114. Smith RC, Singh, A, Infante M, Khandat A, Kloos, A: Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia, *Neuropsychopharmacology* 27:479-497, 2002.
115. Smith, RC, Lindenmayer J-P, Bark N, Warner-Cohen J, Vaidyanathaswamy S, Khandat A: Clozapine, Risperidone, Olanzapine, and Conventional Antipsychotic Drug Effects on Glucose, Lipids, and Leptin in Schizophrenic Patients, *Int. J. Neuropsychopharmacology*, 8:183-194, 2005.
116. Smith RC, Warner-Cohen J, Melissa M, Butler E, Kelly E, Khan A: Effects of Nicotine Nasal Spray on Cognitive Function in Schizophrenia. *Neuropsychopharmacology*, 31: 637-643, 2006.

117. Smith RC, Segman RH, Golcer-Dubner G, Pavlov V, Lerer B: , Allelic Variation in *ApoC3*, *ApoA5* and *LPL* Genes and 1st and 2nd Generation Antipsychotic Effects on Serum Lipids in Patients With Schizophrenia. *Pharmacogenomics* 2008 8:228-236.
118. Greenbaum L, Smith RC, Rigbi A, Strous R, Teltsh O, Kanyas K, Korner M, Lancet D, Ben-Asher E, Lerer B. Further evidence for association of RSG2 gene with antipsychotic-induced Parkinsonism; protective role of a functional polymorphism in the 3'-untranslated region. *Pharmacogenomics* 9:103-110,2009.
119. Smith, RC. Lindenmayer, JP, Davis JM, Cornwell J, Noth, K, Sershen H, Lajtha A: Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder, *Schizophrenia Research*. 110:149-155, 2009.
120. Smith RC, Lindenmayer JP, Davis JM, Kelly E, Viviano TF, Cornwell J, Hu Q, Khan A, Vaidhyanathaswamy S: Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study, *J. Clinical Psychiatry*.70: 1501-1513, 2009.
121. Zhubi A., Veldic M., Puri N.V. , Kadriu B., Caruncho H., Loza I. Sershen H., Lajtha A., Smith RC, Guidotti A., Davis JN, Costa E: An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. *Schizophrenia Research*, 111:115-122, 2009.
122. Smith, R. C., Zhubi A., Sershen H., Lajtha A., Davis J. M., Costa E., Guidotti A., 2010. Varenicline treatment decreases DNMT1 mRNA expression in lymphocytes of schizophrenic patients who are cigarette smokers. *Schizophrenia Research*, 119:269-270, 2010.
123. Smith, R., Lindenmayer J.-P., Hu Q., Kelly E., Viviano T., Cornwell J., Vaidhyanathaswamy S., Marcovina S., Davis J. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study. *Schizophrenia Research*, 120: 204-209, 2010
124. Chen X, L C, Smith RC, Xiao Z, Wang J. Differential sensory gating functions between smokers and non-smokers among drug-naïve first episode schizophrenic patients. *Psychiatry Research*. 188: 327-333, 2011.
125. Lindenmayer, JP, Tedeschi, F, Yusin, Khan A, Kaushik, S, Smith RC, Parakadavil M: Ziprasidone effects on metabolic makers in patients with diabetes and chronic schizophrenia. *Clinical Schizophrenia and Related Psychosis*, 5:185-192, 2012
126. Greenbaum, L., Smith RC, Lorberboym M, Alkelai A., Zozulinsky P, Lifshytz T , Kohn Y, Djaldetti R, Lerer B. Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients. *Psychopharmacology*, DOI 10.1007/s00213-011-2499-6, Epub 24 Sept, 2011.
127. Smith RC, Jin H, Li C, Bark N, Shekhar A, Dwivedi S, *et al* (2013). Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. *Schizophr Res* **143**(1): 18-24.

128. Auta J, Smith RC, Dong E, Tueting P, Sershen H, Boules S, *et al* (2013). DNA-methylation gene network dysregulation in peripheral blood lymphocytes of schizophrenia patients. *Schizophr Res* 150(1): 312-318.

129. Guidotti, A., Auta J., Davis J. M., Dong E., Gavin D. P., Grayson D. R., Sharma R. P., Smith R. C., Tueting P., Zhubi A., 2014. Toward the identification of peripheral epigenetic biomarkers of schizophrenia. *J Neurogenet* 28, 41-52.

130. Smith RC, Boules S, Mattiuz S, Youssef M, Tobe RH, Sershen H, et al. Effects of transcranial direct current stimulation (tDCS) on cognition, symptoms, and smoking in schizophrenia: A randomized controlled study. *Schizophrenia research*. 2015;168(1-2):260-6.

Robert C. Smith
March 31, 2016